Manufacturer of Seleniso

Selinexor (Selinexor) is a targeted therapy drug developed and produced by Karyopharm Therapeutics. Karyopharm is a biopharmaceutical company dedicated to researching, developing and commercializing innovative drugs, mainly focusing on the treatment of cancer, immune diseases and other major diseases. The company has promoted the development of several important targeted therapies through innovative treatments, including selinexole.

Karyopharm Therapeutics was founded in 2008 and is headquartered in Waltham, Massachusetts, USA. The company focuses on developing drugs that interfere with the nuclear export pathway. These drugs can effectively target tumor cells and have significant effects on cancer treatment. Selinisol is a drug developed by Karyopharm. It interferes with the normal function of cancer cells and prevents the growth and spread of tumors by inhibiting Exportin 1 (XPO1). The development of selinesol provides new treatment options for the treatment of hematological malignancies such as multiple myeloma.

Selinesol production is provided byKaryopharm Therapeutics itself, but it also has partnerships with multiple global drug distributors and pharmaceutical companies to ensure broad availability of the drug. The original research and production facilities of the drug are located in the United States. Karyopharm will cooperate with appropriate partners for production and distribution based on the needs of the international market. Through these collaborations, selinesol can be launched in multiple countries and regions to meet the treatment needs of different patients.

In China, Seleniso is sold throughKaryopharm in cooperation with local pharmaceutical companies. Specific sales and distribution channels may be related to the local partner. Selinisol has gradually gained widespread attention since its launch, especially in the treatment of relapsed or refractory multiple myeloma and other diseases, showing significant efficacy. As an imported drug, selinesol is more expensive, but as the drug gradually enters medical insurance, the burden on patients has been reduced.